Genmab — Februar 2018
-
Proceeds to the company are approximately DKK 18.3 million. The increase
corresponds to approx. 0.11% of the companys share capital. -
E L's link 9:47 is the reason why Celg drops 8% https://www.marketwatch.com/story/celgene-shares-drop-6-after-blunder-with-high-profile-drug-2018-02-28
-
CELG startede i 2014 med en licensaftale med upfront på ca $700 mln. Data rullede ind i 2015 og medio 2015 købte de Receptos og midlet ozanimod for $7,2 bn http://ir.celgene.com/releasedetail.cfm?ReleaseID=922090 Nu da fda ikke synes om bivirkningerne kan det hele være tabt.
-
Hej (også)Pensionist - Jeg overraskes skam ikke, vi ved,at de kommer. Men det er da glædeligt, at der fremover vil blive færre, da de jo udvander værdien af øvrige aktier. Jeg har også flere gange udtrykt, at de aktionærer, der var misundelige over, at ansatte i Genmab fik billige aktier, de skulle jo bare selv have købt, dengang kursen var dernede.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind